2. Barnes EL, Loftus EV Jr, Kappelman MD. Effects of race and ethnicity on diagnosis and management of inflammatory bowel diseases. Gastroenterology 2021;160:677-689.
4. Fabián O, Kamaradová K. Morphology of inflammatory bowel diseases (IBD). Cesk Patol 2022;58:27-37.
7. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62(1 Suppl):S47-S64.
9. Liu J, Ayada I, Zhang X, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol 2022;20:e573-e582.
12. Rodriguez-Duque JC, Calleja JL, Iruzubieta P, et al. Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors. Clin Gastroenterol Hepatol 2023;21:406-414.
13. Ampong I, Watkins A, Gutierrez-Merino J, Ikwuobe J, Griffiths HR. Dietary protein insufficiency: an important consideration in fatty liver disease? Br J Nutr 2020;123:601-609.
14. Bauer KC, Littlejohn PT, Ayala V, Creus-Cuadros A, Finlay BB. Nonalcoholic fatty liver disease and the gut-liver axis: exploring an undernutrition perspective. Gastroenterology 2022;162:1858-1875.
17. Sid V, Siow YL, O K. Role of folate in nonalcoholic fatty liver disease. Can J Physiol Pharmacol 2017;95:1141-1148.
18. Yilmaz Y, Ulukaya E, Atug O, Dolar E. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. Eur J Gastroenterol Hepatol 2009;21:1247-1251.
20. Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 2018;68:280-295.
27. Borén J, Packard CJ, Taskinen MR. The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne) 2020;11:474.
29. Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 2017;377:2063-2072.
31. Kovarova M, Königsrainer I, Königsrainer A, et al. The genetic variant I148M in PNPLA3 is associated with increased hepatic retinyl-palmitate storage in humans. J Clin Endocrinol Metab 2015;100:E1568-E1574.
33. Clare CE, Brassington AH, Kwong WY, Sinclair KD. One-carbon metabolism: linking nutritional biochemistry to epigenetic programming of long-term development. Annu Rev Anim Biosci 2019;7:263-287.
37. Jones P, Lucock M, Scarlett CJ, Veysey M, Beckett EL. Folate and inflammation-links between folate and features of inflammatory conditions. J Nutr Intermed Metab 2019;18:100104.
41. Long SL, Gahan CG, Joyce SA. Interactions between gut bacteria and bile in health and disease. Mol Aspects Med 2017;56:54-65.
42. Kuna AT. Serological markers of inflammatory bowel disease. Biochem Med (Zagreb) 2013;23:28-42.
43. Sourianarayanane A, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis 2013;7:e279-e285.
45. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016;65:1038-1048.
48. Chakravarthy MV, Waddell T, Banerjee R, Guess N. Nutrition and nonalcoholic fatty liver disease: current perspectives. Gastroenterol Clin North Am 2020;49:63-94.
49. Mazidi M, Katsiki N, Mikhailidis DP, Banach M. Adiposity may moderate the link between choline intake and non-alcoholic fatty liver disease. J Am Coll Nutr 2019;38:633-639.
51. Campbell JE, Peckett AJ, D’souza AM, Hawke TJ, Riddell MC. Adipogenic and lipolytic effects of chronic glucocorticoid exposure. Am J Physiol Cell Physiol 2011;300:C198-C209.
53. Salehidoost R, Korbonits M. Glucose and lipid metabolism abnormalities in Cushing’s syndrome. J Neuroendocrinol 2022;34:e13143.
54. Rahimi L, Rajpal A, Ismail-Beigi F. Glucocorticoid-induced fatty liver disease. Diabetes Metab Syndr Obes 2020;13:1133-1145.
55. Bath RK, Brar NK, Forouhar FA, Wu GY. A review of methotrexate-associated hepatotoxicity. J Dig Dis 2014;15:517-524.
59. Massart J, Begriche K, Moreau C, Fromenty B. Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res 2017;3(Suppl 1):212-232.
60. Gisbert JP, González-Lama Y, Maté J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007;102:1518-1527.
64. Dean L. Azathioprine therapy and TPMT and NUDT15 genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al., eds. Medical genetics summaries. Bethesda: National Center for Biotechnology Information (US); 2012.
https://www.ncbi.nlm.nih.gov/books/NBK100661/.
65. Grau T, Bonet A, Rubio M, et al. Liver dysfunction associated with artificial nutrition in critically ill patients. Crit Care 2007;11:R10.
70. Singh B, Khan AA, Anamika F, Munjal R, Munjal J, Jain R. Red meat consumption and its relationship with cardiovascular health: a review of pathophysiology and literature. Cardiol Rev 2023 Jun 26 [Epub].
https://doi.org/10.1097/CRD.0000000000000575.
73. Wijarnpreecha K, Kim D, Raymond P, Scribani M, Ahmed A. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. Eur J Gastroenterol Hepatol 2019;31:1121-1128.
75. Principi M, Iannone A, Losurdo G, et al. Nonalcoholic fatty liver disease in inflammatory bowel disease: prevalence and risk factors. Inflamm Bowel Dis 2018;24:1589-1596.
76. Saroli Palumbo C, Restellini S, Chao CY, et al. Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases: a cohort study using transient elastography. Inflamm Bowel Dis 2019;25:124-133.
82. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367-378.
84. Ni Y, Qian L, Siliceo SL, et al. Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. Cell Metab 2023;35:1530-1547.
86. Lapumnuaypol K, Kanjanahattakij N, Pisarcik D, Thongprayoon C, Wijarnpreecha K, Cheungpasitporn W. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol 2018;30:854-860.
87. Boustany A, Rahhal R, Mitri J, et al. The impact of nonalcoholic fatty liver disease on inflammatory bowel disease-related hospitalization outcomes: a systematic review. Eur J Gastroenterol Hepatol 2023;35:1067-1074.
88. Beard JA, Click BH. The burden of cost in inflammatory bowel disease: a medical economic perspective. Curr Opin Gastroenterol 2020;36:310-316.
89. Boursier J, Guillaume M, Bouzbib C, et al. Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 2022;46:101769.
90. Boursier J, Vergniol J, Guillet A, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol 2016;65:570-578.